Legend Biotech's SWOT analysis: stock poised for growth amid challenges

Legend Biotech (LEGN) demonstrates significant momentum, with its stock up 29% over six months, driven by robust performance of its lead CAR-T therapy, Carvykti, which generated $369 million in Q1 2025 sales, exceeding consensus. Despite current losses, LEGN projects profitability by Q2 2026 and anticipates Carvykti sales reaching $1.9 billion in 2025, supported by ambitious manufacturing expansion targeting 10,000 doses by end-2025 and potential approval for earlier multiple myeloma treatment lines. Analysts remain bullish, though challenges include maintaining competitive dominance against emerging therapies and successfully scaling production.

Analysis

Legend Biotech (LEGN) is demonstrating significant commercial momentum, primarily driven by its CAR-T therapy, Carvykti. The product's Q1 2025 sales reached $369 million, a 10% sequential increase that surpassed consensus estimates, contributing to a remarkable 112.46% revenue growth over the last twelve months. The core of the investment thesis now rests on two key pillars: manufacturing scale-up and market expansion into earlier lines of therapy. In partnership with Johnson & Johnson, the company is aggressively expanding production with a stated goal of supplying 10,000 doses by the end of 2025, a critical step to support projected 2025 sales of $1.9 billion. While currently unprofitable, with a projected FY2025 EPS of -$0.25, the company anticipates a pivotal shift to profitability by Q2 2026. This outlook is bolstered by strong clinical data from the CARTITUDE-4 study, which supports Carvykti's use in earlier treatment settings—a catalyst that could substantially increase its addressable market. Key risks remain centered on execution, namely the ability to overcome complex manufacturing hurdles to meet demand and the threat of emerging competition in the dynamic multiple myeloma landscape.

Key Decisions for Investors

• Investors should closely monitor progress toward the manufacturing target of 10,000 Carvykti doses by year-end 2025, as meeting this goal is fundamental to achieving revenue projections and de-risking the operational outlook.
• The primary upside catalyst is the potential regulatory approval and adoption of Carvykti in earlier lines of multiple myeloma treatment; any developments related to the CARTITUDE-4 data should be treated as significant inflection points.
• Given the company's current unprofitability and heavy reliance on a single product, it is prudent to weigh the significant growth potential against execution risks, including potential manufacturing delays and intensifying competition, which could impact the stated Q2 2026 profitability target.
• While the focus is on Carvykti, positive data from pipeline assets like LB1908 or LB2102 would represent a material de-risking event by diversifying future revenue streams beyond multiple myeloma.